LRRC32

LRRC32 Molekülinformation

Englischer Name	Transforming growth factor beta activator LRRC32	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	7	Target-Alias	Leucine Rich Repeat Containing 32，D11S833E，Garpin，Leucine-Rich Repeat-Containing Protein 32，LRRC32，Transforming Growth Factor Beta Activator LRRC32，GARP，Glycoprotein A Repetitions Predominant
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

Englischer Name	Transforming growth factor beta activator LRRC32
Target-Alias	Leucine Rich Repeat Containing 32，D11S833E，Garpin，Leucine-Rich Repeat-Containing Protein 32，LRRC32，Transforming Growth Factor Beta Activator LRRC32，GARP，Glycoprotein A Repetitions Predominant
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	7
Höchste Forschungs- und Entwicklungsphase	Phase 3 Clinical

LRRC32 Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
Fc Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
LR2-H5256	Human	HEK293	Human LRRC32 / GARP / Garpin Protein, Fc Tag				In den Warenkorb legen

Gesamtmenge1

LRRC32 Molekülhintergrund

Leucine-rich repeat protein 32 (LRRC32), also known as GARP (glycoprotein A repetitions predominant). LRRC32 expression promotes the acquisition of a Treg phenotype including reduced cellular proliferation, reduced cytokine secretion, and the capacity to suppress the proliferation of naïve T cells. LRRC32 binds directly to the TGF-beta latency associated peptide (LAP) and tethers latent TGF-beta on the surface of activated Treg cells. The presentation of TGF-beta on Tregs contributes to their ability to suppress naïve T cell proliferation.

LRRC32 Molekülalias

GARP,Garpin,D11S833E

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Livmoniplimab	MGH-8; AGRX-115; ABBV-151; MHG-8; ARGX-115	Phase 3 Clinical	Argenx Se	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Solid tumours	Details
Anti-GARP Chimeric Antigen Receptor T Cell Therapy (Ohio State University Comprehensive Cancer Center)		Phase 1 Clinical	Ohio State University Comprehensive Cancer Center	Glioma	Details
PBA-0111	PBA-0111	Phase 1 Clinical	Pure Biologics SA	Sarcoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms	Details
HLX-6018	HLX-6018; HLX6018	Phase 1 Clinical		Idiopathic Pulmonary Fibrosis	Details
JYB-1907	JYB-1907	Phase 1 Clinical	Jiangxi Jemincare Group Co Ltd	Solid tumours	Details
DS-1055	DS-1055; DS-1055a	Phase 1 Clinical	Daiichi Sankyo Co Ltd	Neoplasms; Solid tumours	Details
HLX-60	HLX-60	Phase 1 Clinical		Lymphoma; Solid tumours	Details